Influence of treatment strategy on serum adiponectin, resistin and angiogenin concentrations in patients with stable multivessel coronary artery disease after one-year follow-up

Kardiologia Polska

Volumn 68, Issue 12, 2010, Pages 1313-1320

  Krȩcki, Radosław ^a   Krzemińska Pakuła, Maria ^a   Peruga, Jan Zbigniew ^a   Szcześniak, Piotr ^b   Lipiec, Piotr ^a   Orszulak Michalak, Daria ^b   Kasprzak, Jarosław Damian ^a  

^a Medical University of Lodz Bieganski Hospital   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adipocytokines; Angiogenesis; Multivessel coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOGENIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; RESISTIN;

ADULT; ANGINA PECTORIS; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; STROKE; TREATMENT PLANNING;

EID: 79952271718     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. American Heart Association, Dallas, Texas 2008.
2. th Ed. WB Saunders, St. Louis 2005: 1281-354.
3. Solomon AJ, Gersh BJ. Management of chronic stable angina: medical therapy, percutaneous transluminal coronary angioplasty and coronary artery bypass surgery. Lessons from the randomized trials. Ann Intern Med, 1998; 128: 216-223.
4. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: Adipocytederived plasma protein adiponectin. Circulation, 1999; 100: 2473-2476. (Pubitemid 30005109)
5. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001; 86: 1930-1935. (Pubitemid 32472900)
6. Koenig W, Khuseyinova N, Baumert J et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle aged men: results from the 18-years follow-up of a large cohort from southern Germany. J Am Coll Cardiol, 2006; 48: 1369-1377. (Pubitemid 44436825)
7. Nakamura Y, Shimada K, Fukuda D et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart, 2004; 90: 528-533. (Pubitemid 38530170)
8. Cavusoglu E, Ruwende C, Chopra V et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J, 2006; 27: 2300-2309. (Pubitemid 44453573)
9. Laughlin GA, Barrett-Connor E, May S et al. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol, 2007; 165: 164-174. (Pubitemid 46096378)
10. Steppan CM, Brown EJ, Wright CM et al. A family of tissue specific resistin-like molecules. Proc Natl Acad Sci, 2001; 98: 502-506. (Pubitemid 32105071)
11. Ohmori R, Momiyama Y, Kato R et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol, 2005; 46: 379-390.
12. Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation, 2003; 108: 736-740. (Pubitemid 36999260)
13. Burnett MS, Lee CW, Kinnaird TD et al. The potential role of resistin in atherogenesis. Atherosclerosis, 2005; 182: 241-248. (Pubitemid 41267191)
14. Weikert C, Westphal S, Berger K et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab, 2008; 93: 2647-2643.
15. Piestrzeniewicz K, Luczak K, Goch JH. Value of blood adipose tissue hormones concentration - adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction. Neuro Endocrinol Lett, 2008; 29: 581-588.
16. Tabibiazar R, Rockson SG. Angiogenesis and the ischaemic heart. Eur Heart J, 2001; 22: 903-918. (Pubitemid 32625213)
17. Khurana R, Simons M, Martin FJ et al. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation, 2005; 112: 1813-1824. (Pubitemid 41368158)
18. Moreno PR, Purushothaman KR, Fuster V et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation, 2004; 110: 2032-2038. (Pubitemid 39331918)
19. Tello-Montoliu A, Marín F, Patel J et al. Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J, 2007; 28: 3006-3011. (Pubitemid 350262264)
20. Thygesen K, Alpert JS, White HD; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. Circulation, 2007; 116: 2634-2653.
21. Werner SG, Jandt E, Krack A et al. Occlusions: relation to duration of occlusion and collateral function growth factors in the collateral circulation of chronic total coronary. Circulation, 2004; 110: 1940-1945. (Pubitemid 39331905)
22. Moulton KS, Heller E, Konerding MA et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation, 1999; 99: 1726-1732. (Pubitemid 29162486)
23. Tenaglia AN, Peters KG, Sketch MH Jr et al. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J, 1998; 135: 10-14. (Pubitemid 28073052)
24. Kwon HM, Sangiorgi G, Ritman EL et al. Adventitial vasa vasorum in balloon-injured coronary arteries: visualization and quantitation by a microscopic three-dimensional computed tomography technique. J Am Coll Cardiol, 1998; 32: 2072-2079. (Pubitemid 29010478)
25. Patel JV, Abraheem A, Chackathayil J et al. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease. J Intern Med, 2009; 265: 562-567.
26. Chung NA, Lydakis C, Belgore F et al. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart, 2003; 89: 1411-1415. (Pubitemid 37465236)
27. Inoue T, Kotooka N, Morooka T et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol, 2007; 100: 569-574. (Pubitemid 47223129)
28. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004; 291: 1730-1737. (Pubitemid 38489895)
29. Otsuka F, Sugiyama S, Kojima S et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol, 2006; 48: 1155-1162. (Pubitemid 44345143)
30. Tamura T, Furukawa Y, Taniguchi R et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J, 2007; 71: 623-630. (Pubitemid 46683348)
31. George J, Patal S, Wexler D et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart, 2006; 92: 1420-1424. (Pubitemid 44578832)
32. Reilly MP, Lehrke M, Wolfe ML et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 2005; 111: 932-939. (Pubitemid 40279897)
33. Hu WL, Qiao SB, Hou Q et al. Plasma resistin is increased in patients with unstable angina. Chin Med J, 2007; 120: 871-875. (Pubitemid 46845926)
34. Lubos E, Messow CM, Schnabel R et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis, 2007; 193: 121-128. (Pubitemid 46783904)